Look back at pharma news in the week to August 13, 2021
By Barbara Obstoj-Cardwell
Among last week’s notable news, US biotech firm bluebird bio revealed a double whammy on Wednesday, when it announced a US Food and Drug Administration clinical hold on its gene therapy Skysona (eli-cel) as well as its decision to pull out of Europe because of difficulties in gaining reimbursement for its products. AstraZeneca and partner FibroGen suffered a setback with the FDA issuing a complete response letter (CRL) on their anemia of chronic kidney disease candidate roxadustat. On the deal-making front, US biotech Seagen last week announced a licensing agreement with China’s RemeGen to develop disitamab vedotin as a treatment for various cancers, worth up to $2.2 billion. mRNA specialist Moderna released new data showing its COVID-19 vaccine Spikevax generated neutralizing antibodies against variants.
bluebird bio downgrade to market perform following business update
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze